Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-κB and inhibition of p53 activation

Cellular Immunology

Volumn 282, Issue 2, 2013, Pages 100-105

  Tsolmongyn, Bilegtsaikhan ^a   Koide, Naoki ^a   Odkhuu, Erdenezaya ^a   Haque, Abedul ^a   Naiki, Yoshikazu ^a   Komatsu, Takayuki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Lipopolysaccharide; NF B; P53; Toll like receptor; Valproic acid

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE 3; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PARTHENOLIDE; PIFITHRIN ALPHA; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TOLL LIKE RECEPTOR; VALPROIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; MACROPHAGE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-5-(3-CARBOXYMETHOXYPHENYL)-2-(4-SULFOPHENYL)-2-H-TETRAZOLIUM; APOPTOSIS; B-CELL LYMPHOMA 2; BAX; BCL-2; BCL-2-ASSOCIATED X PROTEIN; C-JUN N-TERMINAL KINASE; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; HDAC; HISTONE DEACETYLASE; JNK; LIPOPOLYSACCHARIDE; LPS; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; MTT; NF-ΚB; NUCLEAR FACTOR-ΚB; P53; PARP; PFT-Α; PIFITHRIN-Α; POLY (ADP-RIBOSE) POLYMERASE; TERMINAL DEOXYRIBONUCLEOTIDYL TRANSFERASE-MEDIATED DUTP NICK END LABELING; TLR; TOLL-LIKE RECEPTOR; TUNEL; VALPROIC ACID; VPA;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOBLOTTING; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRILES; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; SULFONES; TOLL-LIKE RECEPTORS; TUMOR SUPPRESSOR PROTEIN P53; VALPROIC ACID;

EID: 84879165919     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.04.011     Document Type: Article

References (35)

1. Gerstner T., Bell N., König S. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin. Pharmacother. 2008, 9:285-292.
2. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 2009, 107:600-608.
3. Smith K.T., Workman J.L. Histone deacetylase inhibitors: anticancer compounds. Int. J. Biochem. Cell Biol. 2009, 41:21-25.
4. Häcker S., Karl S., Mader I., Cristofanon S., Schweitzer T., Krauss J., et al. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 2011, 30:2275-2281.
5. Chen X., Wong J.Y., Wong P., Radany E.H. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol. Cancer Res. 2011, 9:448-461.
6. Kawano T., Akiyama M., Agawa-Ohta M., Mikami-Terao Y., Iwase S., Yanagisawa T., et al. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int. J. Oncol. 2010, 37:787-795.
7. Condorelli F., Gnemmi I., Vallario A., Genazzani A.A., Canonico P.L. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br. J. Pharmacol. 2008, 153:657-668.
8. Shen Y., White E. p53-Dependent apoptosis pathways. Adv. Cancer Res. 2001, 82:55-84.
9. Green D.R., Kroemer G. Cytoplasmic functions of the tumor suppressor p53. Nature 2009, 458:1127-1130.
10. Zilfou J.T., Lowe S.W. Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 2009, 1:a001883.
11. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 2010, 11:373-384.
12. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell Biochem. 2010, 336:25-37.
13. Henson E.S., Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 2006, 18:2089-2097.
14. Peter A.T., Dhanasekaran N. Apoptosis of granulosa cells: a review on the role of MAPK-signaling modules. Reprod. Domest. Anim. 2003, 38:209-213.
15. Hassan F., Islam S., Mu M.M., Ito H., Koide N., Mori I., et al. Lipopolysaccharide prevents doxorubicin-induced apoptosis in RAW 264.7 macrophage cells by inhibiting p53 activation. Mol. Cancer Res. 2005, 3:373-379.
16. Islam S., Hassan F., Tumurkhuu G., Ito H., Koide N., Mori I., et al. Lipopolysaccharide prevents apoptosis induced by brefeldin A, an endoplasmic reticulum stress agent, in RAW 264.7 cells. Biochem. Biophys. Res. Commun. 2006, 340:589-596.
17. Tumurkhuu G., Koide N., Dagvadorj J., Noman A.S., Khuda I.I., Naiki Y., et al. B1 cells produce nitric oxide in response to a series of toll-like receptor ligands. Cell Immunol. 2010, 261:122-127.
18. Dagvadorj J., Naiki Y., Tumurkhuu G., Noman A.S., Iftakhar-E-Khuda I., Komatsu T., et al. Tumor necrosis factor-a augments lipopolysaccharide-induced suppressor of cytokine signaling 3 (SOCS-3) protein expression by preventing the degradation. Immunology 2010, 129:97-104.
19. Mackey T.J., Borkowski A., Amin P., Jacobs S.C., Kyprianou N. Bcl-2/Bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998, 52:1085-1090.
20. Schneider G., Krämer O.H. NFκB/p53 crosstalk-a promising new therapeutic target. Biochim. Biophys. Acta 2011, 1815:90-103.
21. Lee T.L., Yeh J., Friedman J., Yan B., Yang X., Yeh N.T., et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int. J. Cancer 2008, 122:1987-1998.
22. Yamamoto M., Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol. Res. Pract. 2010, 2010:240365.
23. O'Neill L.A. The interleukin-1 receptor/toll-like receptor superfamily: 10years of progress. Immunol. Rev. 2008, 226:10-18.
24. Elknerova K., Myslivcova D., Lacinova Z., Marinov I., Uherkova L., Stöckbauer P. Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence. Neoplasma 2011, 58:35-44.
25. Yagi Y., Fushida S., Harada S., Kinoshita J., Makino I., Oyama K., et al. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J. Exp. Clin. Cancer Res. 2010, 29:149.
26. Ziauddin M.F., Yeow W.S., Maxhimer J.B., Baras A., Chua A., Reddy R.M., et al. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 2006, 8:446-457.
27. Kawagoe R., Kawagoe H., Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk. Res. 2002, 26:495-502.
28. Pessayre D., Mansouri A., Haouzi D., Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 1999, 15:367-373.
29. Dey A., Tergaonkar V., Lane D.P. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat. Rev. Drug Discov. 2008, 7:1031-1040.
30. Tergaonkar V., Pando M., Vafa O., Wahl G., Verma I. P53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002, 1:493-503.
31. Komarova E.A., Krivokrysenko V., Wang K., Neznanov N., Chernov M.V., Komarov P.G., et al. P53 is a suppressor of inflammatory response in mice. FASEB J. 2005, 19:1030-1032.
32. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
33. Berendsen S., Broekman M., Seute T., Snijders T., van Es C., de Vos F., et al. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opin. Invest. Drugs 2012, 21:1391-1415.
34. Gerstner T., Bell N., König S. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin. Pharmacother. 2008, 9:285-292.
35. Takai N., Kawamata N., Gui D., Said J.W., Miyakawa I., Koeffler H.P. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004, 101:2760-2770.